Real-world studies confirm that pairing LONSURF with bevacizumab increases efficacy in patients with metastatic colorectal cancer
Increased efficacy with the combination was demonstrated broadly across this population and specifically in Black patients with the disease
PRINCETON, N.J., Jan. 24, 2025 /PRNewswire/ — Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced that it will share real-world data about the crucial role of LONSURF® (trifluridine/tipiracil) in a combination treatment for metastatic colorectal cancer (mCRC) during the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium, January 23-25 in San Francisco.
In two abstracts, Taiho will present findings from real-world retrospective studies demonstrating that pairing LONSURF with bevacizumab, rather than administering LONSURF alone, improves clinical outcomes for the mCRC patient population, including Black patients.
Orally administered LONSURF pairs the chemotherapy trifluridine, a nucleoside metabolic inhibitor, with tipiracil hydrochloride, a thymidine phosphorylase inhibitor that prolongs trifluridine’s ability to stay active in the body. In the U.S., LONSURF’s indication in mCRC is for use alone or in combination with bevacizumab, an anti-angiogenic drug.
“We’re pleased to present substantial real-world evidence confirming LONSURF’s role as an effective regimen for patients with metastatic colorectal cancer,” said Tehseen Salimi, MD, MHA, Senior Vice President and Head of Medical Affairs, Taiho Oncology. “At Taiho Oncology, we are dedicated to improving clinical outcomes and reducing patient burden by analyzing the real-world impact of our treatments and making patients and providers aware of the results.”
Adding bevacizumab to LONSURF improves clinical outcomes for patients with mCRC
The larger of the two studies included 3,680 adult patients with mCRC, 3,151 of whom received LONSURF alone and 529 of whom received LONSURF plus bevacizumab. Researchers pulled data about patients and their treatments from electronic medical records and claims in the ConcertAI RWD360™ dataset.
Investigators found that patients who took LONSURF plus bevacizumab, in the usual care setting, experienced a median real-world overall survival of 9.4 months (95% confidence interval [CI] 8.0-10.1) versus 6.4 months (95% CI 6.1-6.6; p